Klaipeda Children Hospital
- Address
- lock Available on a paid plan
Klaipeda Children Hospital - Pediatric Infectious Disease Research
Klaipeda Children Hospital serves as a specialized clinical research center dedicated to advancing pediatric care through participation in innovative therapeutic studies. The facility demonstrates particular expertise in evaluating novel antimicrobial treatments for pediatric patients, focusing on evidence-based approaches to managing infectious diseases in children.
- Acute Bacterial Skin and Skin Structure Infections (ABSSSI) treatment protocols
- Intravenous antibiotic therapy safety and tolerability in pediatric populations
- Single-dose antimicrobial treatment strategies for bacterial infections
The hospital participates in multicenter, randomized clinical trials designed to evaluate cutting-edge therapeutic options for pediatric patients. Their involvement in studies assessing oritavancin (ORBACTIV and KIMYRSA) demonstrates commitment to investigating advanced treatment modalities that may improve outcomes and convenience for children suffering from serious bacterial infections, while carefully monitoring safety profiles specific to younger patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klaipeda Children Hospital
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety and Tolerability of Single-Dose Intravenous Oritavancin Versus Standard Care in Pediatric Acute Bacterial Skin and Skin Structure Infections | Melinta Therapeutics LLC | Phase II | Not Recruiting | May 2023 | Nov 2025 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aztreonam | 1 | Unknown | 2023-05-02 | 2023-05-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.